BioSpace News Archive

Financing will advance its musculoskeletal product through a clinical proof of activity trial as well as continue the discovery and development of its ongoing pipeline of microbial-based products for human health and well-being.

EXUMA Biotech Corporation, a clinical-stage biotechnology company discovering and developing CAR-T products and delivery solutions for liquid and solid tumors, is pleased to announce that Dr. Sid Kerkar, M.D., has joined the company’s senior leadership team as Vice President Oncology, Research & Development effective September 2020.

Cognition Therapeutics, Inc. , a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that a peer-reviewed manuscript, entitled, “Icelandic Mutant Human Amyloid-β 1-42 Peptide Forms Fewer Oligomers with Lower Binding Affinity than Wild-Type Peptide,” has been published online in the Journal of Neurochemistry ( doi:10.1111/jnc.15212 ). It has b

iCAD, Inc. announced that new, promising clinical results supporting the Xoft® Axxent® Electronic Brachytherapy System® for the treatment of recurrent glioblastoma, will be presented at the European Association of Neurosurgical Societies Virtual Congress, October 19- 21, 2020.

Reflect Scientific, Inc. (Symbol: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries, announces a recently awarded patent for a cryogenic modular shipping unit that can reliably and uniformly maintain its payload at temperatures as low as -90 degrees Celsius, making it an ideal system for cold chain management of biologics like COVID 19 vaccines. The cryogenic system provides the

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapies for neurodegenerative diseases, announced the presentation of a poster titled, “MSC-NTF Exosomes: A Novel Therapeutic Modality in the Mouse LPS-induced ARDS model Analysis” at the NYSCF Conference Meeting, being held virtually.

42 abstracts featuring additional insights into roxadustat and anemia of chronic kidney disease to be presented

Topas Therapeutics GmbH, a Hamburg, Germany-based private platform company leveraging the natural immune tolerance induction capabilities of the liver, announced the successful closing of a €22 million Series B financing round.

Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, announced the appointment of industry veteran Gregory I. Berk, MD, to its Board of Directors.

AntiCancer, Inc., a worldwide leader in cancer research and the pioneer of patient-derived mouse models of cancer, announced today it has filed a second lawsuit against Certis Oncology Solutions, Inc. The companies are locked in a long-running legal dispute over hundreds of “immortalized” patient tumor samples which AntiCancer developed and alleges were stolen by Certis, a controversial startup which was originally founde